The TREM2 agonistic antibody AL002 in early Alzheimer's disease: a phase 2 randomized trial
{{output}}
Triggering receptor expressed on myeloid cells 2 (TREM2) regulates microglial function and is implicated in Alzheimer's disease (AD) pathogenesis. Here we conducted a phase 2, randomized, double-blind, placebo-controlled trial of a humanized TREM2 agonistic m... ...
